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Abstract
AIM: To analyze the prevalence, length and predictors 
of hospitalization in the biological era in the population-
based inception cohort from Veszprem province.
METHODS: Data of 331 incident Crohn’s disease 
(CD) patients diagnosed between January 1, 2000 and 
December 31, 2010 were analyzed (median age at 
diagnosis: 28; IQR: 21-40 years). Both in- and outpatient 
records were collected and comprehensively reviewed.
RESULTS: Probabilities of first CD-related hospitali-
zation and re-hospitalization were 32.3%, 45.5%, 
53.7% and 13.6%, 23.9%, 29.8%, respectively after 
one, three and five years of follow-up in Kaplan-Meier 
analysis. First-year hospitalizations were related to 
diagnostic procedures (37%), surgery or disease activity 
(27% and 21%). Non-inflammatory disease behavior 
at diagnosis (HR = 1.32, P = 0.001) and perianal 
disease (HR = 1.47, P = 0.04) were associated with 
time to first CD-related hospitalization, while disease 
behavior change (HR = 2.38, P  = 0.002) and need for 
steroids (HR = 3.14, P  = 0.003) were associated with 
time to first re-hospitalization in multivariate analyses. 
Observational Study
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Early CD-related hospitalization (within the year of 
diagnosis) was independently associated with need 
for immunosuppressives (OR = 2.08, P = 0.001) and 
need for surgeries (OR = 7.25, P < 0.001) during the 
disease course.
CONCLUSION: Hospitalization and re-hospitalization 
rates are still high in this cohort, especially during 
the first-year after the diagnosis. Non-inflammatory 
disease behavior at diagnosis was identified as the 
pivotal predictive factor of both hospitalization and re-
hospitalization.
Key words: Crohn’s disease; Hospitalization; Recurrence; 
Predictor; Population-based; Biological therapy
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Recent data on hospitalization rates in Crohn’
s disease (CD) are lacking from population-based 
studies. In the present study our aim was to analyze 
the prevalence, cause and predictors of hospitalization 
and re-hospitalization in the population-based inception 
cohort from Veszprem province. Relatively high rates 
of CD-related hospitalizations and re-hospitalizations 
were found in our cohort, especially during the first 
year after the diagnosis. Non-inflammatory disease 
behavior at diagnosis, behavior change in patients 
with initial B1 behavior, perianal disease and total AZA 
and anti-TNF exposure was associated with the time 
to first CD-related hospitalization. Early CD-related 
hospitalization was associated with non-inflammatory 
disease behavior, perianal or internal fistulizing disease, 
need for immunosuppressives and need for surgeries 
during the disease course.
Golovics PA, Lakatos L, Mandel MD, Lovasz BD, Vegh Z, 
Kurti Z, Szita I, Kiss LS, Pandur T, Lakatos PL. Prevalence and 
predictors of hospitalization in Crohn’s disease in a prospective 
population-based inception cohort from 2000-2012. World J 
Gastroenterol 2015; 21(23): 7272-7280  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v21/i23/7272.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v21.i23.7272
INTRODUCTION
Inflammatory bowel diseases (IBD) are chronic, 
progressive inflammatory diseases leading to disability. 
Crohn’s disease (CD) has a variable course; the 
majority of patients experience multiple relapses, 
while 25% experience chronic continuous symptoms 
and eventually developing complications necessitating 
hospitalization or surgery[1]. Crohn’s disease treated 
mostly in the outpatient setting; the need for hospita­
lization is regarded as an important outcome and a 
surrogate marker of disease severity. Both medical and 
surgical hospitalization events contribute significantly 
to the cost burden of the disease[2].
Relatively limited data are available on the hos­
pitalization or re­hospitalization rates in IBD from 
in population-based cohorts. In a recent meta-
analysis published in 2012, authors summarized the 
hospitalization and surgery rates published from 
population­based cohorts[3]. The majority of studies 
were published before the biological era and the 
concomitant paradigm shift in patient management 
including early stratification, tight monitoring, and 
tailored treatment strategy[4]. Reported hospitalization 
rates were high, ranging between 25% and 83% 
within five years of diagnosis, with the highest rate in 
the year following diagnosis. There was a significant 
geographic variation and a trend toward decreasing 
surgery rates. Surgery rates varied from 10% to 
35% in the first year, and between 18%­59% and 
29%-61% after 5 and 10 years, respectively. In 
addition, predictors for first hospitalization - including 
markers of complicated disease; location (upper GI, 
ileocolonic, small bowel), complicated disease behavior, 
age at onset, and gender ­ were hardly studied[5,6].
In recent years, a significant emphasis was placed 
on early patient stratification based upon the identifi­
cation of predictive factors[7]. Phenotypic classification 
of Crohn’s disease plays an important role in deter­
mining treatment methodology, as it generally assists 
in predicting the likely clinical course[8,9]. The complex 
evaluation of clinical presentation, endoscopic findings, 
fecal, serological, and routine laboratory tests ­ as 
well as early treatment factors - is recommended. For 
example, in a landmark paper by Beaugerie et al[7], 
initial requirements for steroid use (OR = 3.1), an 
age below 40 years (OR = 2.1), and the presence of 
perianal disease (OR = 1.8) were associated with the 
development of disability. However, it is not clear if a 
need for early hospitalization should be regarded as an 
independent marker of later disease course or only a 
marker of disease severity.
Therefore, the aim of the present study was to 
prospectively analyze the prevalence, length, cause, 
and predictors of hospitalizations and re­hospitalizations 
in a population­based inception cohort from Veszprem 
province in the biological era, in patients diagnosed 
between January 1, 2000 and December 31, 2010, with 
follow-up until December 31, 2012. In addition, our aim 
was to study if early hospitalization was associated with 
the later disease course or treatment algorithm.
MATERIALS AND METHODS
Patients
Three hundred thirty-one incident CD patients (M/F: 
176/155, median age at diagnosis: 28 years; IQR 
21-40 years, median follow-up: 6 years; IQR 2-9 
years) diagnosed between January 1, 2000 and 
December 31, 2010 were included in this study. Both 
in­ and outpatient records were collected from the 
Veszprem province database and comprehensively 
Table 1  Demographic data and disease characteristics of the 
inception patients with Crohn’s disease  n  (%)
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reviewed. The clinical characteristics of the patients are 
presented in Table 1.
A more detailed description of our data collection 
method, case ascertainment, geographical and 
socioeconomic background of the province, and the 
Veszprem Province IBD Group was published in our 
previous epidemiological studies[10,11].
Methods
Diagnosis was based on the Lennard­Jones Criteria[12]. 
The disease phenotype (age at onset, duration, 
location, and behavior) was determined according 
to the Vienna and Montreal Classifications (perianal 
disease was from the beginning separately registered 
and cases diagnosed before 2005 were reclassified 
according to the Montreal system in 2005)[13]. Medical 
records, including data regarding the presence of 
major extraintestinal manifestations (EIM), previous 
frequency of flare-ups (frequent flare-up: > 1 clinical 
relapse/year[14]), previous surgical procedures 
(resections or perianal procedures), the presence of 
familial IBD, smoking habits, and perianal involvement, 
were determined by a thorough review of the patients’ 
medical charts, which had been collected in a uniform 
format. Medical therapy (steroid, immunosuppressive, 
or biological therapy) was registered with the starting 
date of the first prescription. Biological therapy was 
first approved (infliximab) in the inpatient setting in 
1998, while adalimumab was registered in 2008. The 
reimbursement of biologicals has changed, and anti­
TNFs are now approved for outpatient use.
All­cause and IBD­related hospitalization events 
(including medical­surgical complications) were 
registered throughout the disease course. Clinical, 
laboratory data, drug use, hospitalizations ­ including 
surgeries ­ were captured prospectively in all patients 
from the time of the diagnosis. In referral patients, 
disease phenotype, course, and hospitalization events 
were captured retrospectively at the time of the 
referral visit and prospectively thereafter.
Definitions: Major surgical events were defined 
as major esophageal, stomach, and duodenum 
resections, major intestinal and rectal resections, 
laparotomy, extensive gastrointestinal procedures, and 
gastrostomy, ileostomy and colostomy procedures, 
while minor surgeries were defined as perianal fistula 
drainage, fistulectomy, and abscess drainage. IBD-
related hospitalizations included medical or surgical 
hospitalizations related to disease flare. Other events 
and patients hospitalized solely for diagnostic purposes 
(end not due to severe clinical activity) were excluded 
from the prediction analysis when we assessed 
the predictive potential of the importance of early 
hospitalizations. Disease behavior change was defined 
as a change from non­stricturing, non­penetrating (B1) 
to either stricturing (B2) or penetrating (B3) disease.
Ethical permission
The central coordination and database management 
was completed at the 1st Department of Internal 
Medicine, Semmelweis University (by PLL). The study 
was approved by the Semmelweis University Regional 
and Institutional Committee of Science and Research 
Ethics and by the Csolnoky F. Province Hospital 
Institutional Committee of Science and Research Ethics 
and written informed consent was obtained from all 
patients prior to enrollment.
Statistical analysis
Variables were tested for normality by Shapiro Wilk’s 
W-test. The χ 2­test and χ 2­test with Yates correction, 
McNemar test, and logistic regression analysis were 
used to assess the association between categorical 
variables. Odds ratios (OR) were calculated. Variables 
with a P < 0.2 in univariate analysis were included in 
multivariate testing with anti-TNF type and gender 
added arbitrarily. Cox regression analysis was used 
for survival analysis. Results for continuous variables 
are expressed as median (interquartile range, IQR) 
unless otherwise stated. Peter L Lakatos performed 
all statistical analysis and statistical methods were 
reviewed by a biostatistician (Dr Peter Vargha, 
Semmelweis University). For statistical analysis, SPSS
® 20.0 (SPSS Inc., Chicago, IL) was used. A P value < 
CD n = 331
Males 176 (53.2)
Age at presentation (yr) 28; IQR 21-40
Follow-up (yr) 6; IQR: 2-9
Familial IBD   59 (17.8)
Location
      L1 115 (34.7)
      L2 105 (31.7)
      L3 108 (32.6)
      L4 only   4 (0.9)
Behavior at diagnosis
      B1 182 (55.0)
      B2   66 (19.9)
      B3   83 (25.1)
Perianal disease   59 (17.8)
Arthritis   85 (25.7)
Ocular 12 (3.6)
Cutaneous 29 (8.8)
Steroid use 194 (58.6)
Azathioprine use 197 (59.5)
Biological use 27 (8.2)
Smoking habits at diagnosis
      No 147 (44.4)
      Ex   46 (13.9)
      Yes 138 (41.7)
CD: Crohn’s disease.
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0.05 was considered significant.
RESULTS
Patient phenotype, previous disease course and 
exposure to medications
The clinical characteristics of the patients are summarized 
in Table 1. The ileal, colonic and ileocolonic localization 
rate was nearly equal; close to two­thirds of patients 
had inflammatory disease behavior, while the perianal 
involvement was 17.8%. During the median six-
year follow­up, total steroid and AZA exposure was 
approximately 60%, and just fewer than 10% of 
patients were exposed to biologicals.
Hospitalization rates
The probability of first all-cause and IBD-related 
hospitalization was 58%/32.3%, 74.4%/45.5% and 
78.9%/53.7% after one, three, and five years of 
follow-up in a Kaplan-Meier analysis (Figure 1). The 
probability of hospitalization due to major surgery was 
18.7%, 27.9% and 35.9% after one, three, and five 
years of follow-up. The probability of the first all-cause 
and IBD-related re-hospitalization was 29.6%/13.6%, 
32.5%/23.9% and 49.7%/29.8% after one, three and 
five years (Figure 2).
The main reasons for hospitalization in the first 
years were diagnostic procedures (37%), IBD­related 
surgery (27.2%), and disease activity (21.1%) 
(Figure 3). The relative frequency of surgery-related 
hospitalizations remained stable (23%­27% in years 
1­10), while the proportion of non­IBD related hospital 
admissions increased after year three.
The mean duration of hospital admissions was 
248 d per 100 patient­years follow­up for diagnostic 
procedures, 196, 300, 82, and 161 d per 100 patient­
years follow­up for IBD­related medical, major­, and 
minor­surgical hospitalizations, and IBD­unrelated 
hospitalization events within one year of diagnosis. 
Corresponding rates were 33, 48, 13, and 21 d, and 
58, 51, 5, and 57 d per 100 patient­years follow­
up for CD­related medical, major­, minor­surgical 
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Figure 1  Probability of first all-cause (A) and Crohn’s disease-related (B) hospitalization.
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Figure 2  Probability of first all-cause (A) and Crohn’s disease-related (B) re-hospitalization.
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hospitalizations, and IBD­unrelated events two and 
three to four years after the diagnosis.
Predictors of hospitalization
Non-inflammatory disease behavior at diagnosis (PLogRank 
< 0.001, HR = 1.38, 95%CI: 1.18-1.61, P < 0.001), 
behavior change in patients with initial B1 behavior 
(PLogRank < 0.001, HR = 2.91, 95%CI: 1.84-4.61, P < 
0.001), perianal disease (PLogRank < 0.001, HR = 1.80, 
95%CI: 1.27-2.55, P = 0.001), total AZA and anti-
TNF exposure (PLogRank = 0.038, HR = 1.36, 95%CI: 
0.99-1.86, P = 0.059 and PLogRank = 0.017, HR = 1.69, 
95%CI: 1.04-2.72, P = 0.033) but not gender, age at 
diagnosis, era of diagnosis (2000­2005 vs 2006­2010), 
smoking, and steroid exposure were significantly 
associated with time to first CD-related hospitalization 
(after excluding cases hospitalized for diagnosis) in 
a Kaplan-Meier and Cox-regression analysis. Non-
inflammatory disease behavior at diagnosis (HR = 
1.32, 95%CI: 1.11-1.55, P = 0.001), perianal disease 
(HR = 1.47, 95%CI: 1.02-2.12, P = 0.04) and disease 
behavior change (HR = 2.97, 95%CI: 1.78-4.96, P < 
0.001) were associated with time to first CD-related 
hospitalization in multiple Cox-regression analysis.
Phenotype change from B1 (PLogRank < 0.001, HR = 
2.93, 95%CI: 1.72-4.97, P < 0.001), arthritis (PLogRank = 
0.02, HR = 1.58, 95%CI: 1.04-2.38, P = 0.03), need for 
steroids (PLogRank < 0.001, HR = 2.55, 95%CI: 1.60-4.07, 
P < 0.001) and total AZA and anti-TNF exposure (PLogRank 
< 0.001, HR = 2.45, 95%CI: 1.54-3.89, P < 0.001 
and PLogRank = 0.03, HR = 1.83, 95%CI: 1.02-3.29, 
P = 0.041), but not gender, age at diagnosis, era of 
diagnosis (2000­2005 vs 2006­2010), or smoking were 
associated with time to first CD-related re-hospitalization 
in a Kaplan-Meier and Cox-regression analysis. Behavior 
change from B1 (HR = 2.38, 95%CI: 1.36-4.16, P = 
0.002), and need for steroids (HR = 3.14, 95%CI: 
1.46-6.74, P = 0.003) were associated with time to first 
CD­related hospitalization in multiple Cox­regression 
analyses.
Early hospitalization: a marker of later disease course
Early IBD­related hospitalization was associated with 
age at onset according to the Montreal classification 
(P = 0.026), behavior (P < 0.001), non-inflammatory 
disease behavior at diagnosis (OR = 3.19, 95%CI: 
1.95-5.22, P < 0.001), development of perianal (OR 
= 2.35, 95%CI: 1.19-4.64, P = 0.01) and/or internal 
fistulizing disease (OR = 3.82, 95%CI: 1.56-9.34, P 
= 0.002), presence of anemia (OR = 1.83, 95%CI: 
1.15-2.86, P = 0.01), but not location, calendar year 
at diagnosis, presence of other EIMs, familial disease, 
smoking, or total steroid exposure.
In addition, early IBD­related hospitalization 
(after excluding the cases hospitalized for diagnostic 
purposes as well) was associated with disease behavior 
(P < 0.001), non-inflammatory disease behavior (OR 
= 5.04, 95%CI: 5.15-8.05, P < 0.001), perianal (OR 
= 2.06, 95%CI: 1.16-3.69, P = 0.013), or internal 
fistulizing disease (OR = 6.00, 95%CI: 2.69-13.7, P < 
0.001) for need for immunosuppressives (OR = 2.08, 
95%CI: 1.33-3.26, P = 0.001), and need for surgery 
or multiple surgeries (OR = 7.25, 95% CI: 4.34-12.1, 
P < 0.001) during the disease course, but not for age 
at onset or presence of anemia. In addition early IBD-
related hospitalization was associated with disease 
location (P = 0.016) and smoking (P = 0.02) and with 
a trend towards more early hospitalizations in patients 
diagnosed in 2007­2012 (P = 0.06).
In a logistic regression model, the need for 
azathioprine was independently associated with early 
IBD­related hospitalization (P = 0.01, OR = 2.03), 
perianal disease (P =0.046, OR = 2.07), age at 
diagnosis (P = 0.002) and presence of arthritis (P < 
0.001, OR = 2.96), but not with non-inflammatory 
behavior or era of diagnosis. (Table 2) In the same 
model, the need for early IBD­related hospitalization 
(P < 0.001, OR = 5.80), non-inflammatory behavior 
(P < 0.001, OR = 2.15), colonic location (P = 0.002, 
OR = 0.33) and, anaemia at presentation (P < 0.001, 
OR = 4.39), but not with smoking or perianal disease, 
were associated with the need for surgery (Table 2) 
The same associations were confirmed also in a time 
dependent Cox model, where the era of diagnosis was 
not associated with the need for surgery in this cohort 
(data not shown).
DISCUSSION
Hospitalization and re-hospitalization rates were 
relatively high in this population­based, inception 
cohort CD study from Eastern Europe. A significant 
proportion of patients were hospitalized for diagnostic 
workup. The mean duration of hospitalization was 
four- to fivefold higher in the first year after diagnosis 
compared to the subsequent years one to three 
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
1               2             3-4           5-6           7-10
Year from diagnosis
Other
Surgery
Figure 3  Cause of hospitalization in patients with Crohn’s disease 
according to the year of follow-up.
IBD
Diagnosis
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Table 2  Predictive factors for immunosuppressive use and need for major inflammatory bowel diseases-related abdominal surgery
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years. Complicated disease behavior at diagnosis was 
identified as the key predictive factor for hospitalization 
and re-hospitalization. The need for early hospita-
lization was independently associated with the later 
disease course and clinically significant outcomes (need 
for immunosuppressives and surgery).
Relatively few data are available on hospitalization 
rates from population-based cohorts. In the early 
population­based studies between 1960 and 1985, 
the hospitalization rate was exceedingly high (e.g., 
in Denmark 83% of the CD patient hospitalized were 
admitted at least once within the first year after 
diagnosis, with admissions at a rate of about 20% 
per year over the next five years)[15]. In the same 
time period, the surgical rate was 35%, 8%, and 5% 
in the year of diagnosis, the second and third year 
following diagnosis, respectively. The cumulative risk 
was 61% within 10 years of diagnosis[16]. Of note, in a 
recent study by a Danish group, 66% of CD patients 
had at least one hospitalization event within seven 
years of diagnosis[17]. In contrast, in the early 2000s 
we found lower IBD-related hospitalization rates: 
32.3% in the first year, 6.6%, and 4.1% annually in 
the second and third, and the fourth and fifth years 
after diagnosis. Interestingly, 56% of IBD-related 
hospitalization events were surgical hospitalizations 
within one year of diagnosis, while 40% to 48% of CD­
related hospitalization events were surgical admissions 
in the subsequent nine years. Without question, re-
hospitalization rates received inadequate study. The 
CD­related re­hospitalization rates in the present study 
were 13.6%, 23.9% and 29.8% within one, three 
and five years of diagnosis. Similarly, in the 1990s in 
a population­based study from Canada approximately 
25% of subjects with CD were admitted annually, 
while only 4% were readmitted within one year and 
56% was readmitted at least once. Nearly half of the 
hospitalizations were related to major surgery[18]. 
The annual age-adjusted hospitalization rate declined 
significantly from 29.2 to 26.9 per 100000 persons 
over the seven years of the study. Comparable rates 
were also reported from a more recent Canadian 
study between 1988 and 2008[19]. The cumulative IBD-
related hospitalization rate was 26% and 36% after 
one and five years. In concordance with the present 
study, the highest hospitalization rates were within the 
first year of diagnosis and were no different according 
to the calendar year of diagnosis.
Lower ten­year cumulative hospitalization rates 
were also reported in the EC­IBD study[20]. The 
cumulative risk of hospitalization was 52.7% within 
ten years of diagnosis, with considerable geographical 
differences. Furthermore, hospitalization rates decreased 
after the first year of the diagnosis. Finally, even 
lower early hospitalization rates were reported in 
the very recent, population­based EpiCom study in 
patients diagnosed in 2010[21]. Cumulative CD-related 
hospitalization rates were 20% and 16% in western 
and eastern European centers, with 42% and 35% of 
events related to surgery, respectively.
Few data are available on the duration of hospitali-
zation. In a study from Manitoba[6], the mean annual 
Univariate analysis Logistic regression
Immunosuppressive use
      Early IBD-related hospitalization P = 0.001, OR = 2.08 P = 0.01, OR = 2.03
95%CI: 1.33-3.26 95%CI: 1.18-3.49
      Perianal disease P = 0.01, OR = 2.28 P = 0.046, OR = 2.07
95%CI: 1.21-4.30 95%CI: 1.01-4.22
      Age at diagnosis1 P < 0.001 P = 0.002
      Location P = 0.016 for location NS 
      Smoking P = 0.054 P = 0.06
      Non-inflammatory behavior P = 0.06 NS
      Arthritis P = 0.03, OR = 1.76 P < 0.001, OR = 2.96
95%CI: 1.05-2.98 95%CI: 1.63-5.39
      Steroid use (any time) P < 0.001, OR = 5.78 -
95%CI: 3.57-9.35
Major IBD-related abdominal surgery
      Early IBD-related hospitalization P < 0.001, OR = 7.24 P < 0.001, OR = 5.80
95%CI: 4.34-12.1 95%CI: 3.20-10.5
      Non-inflammatory behavior P < 0.001, OR = 5.38 P < 0.001, OR = 2.15
95%CI: 3.30-8.76 95%CI: 1.56-2.94
      Location P < 0.0012 P = 0.02 for location,
P = 0.002, OR = 0.33
95%CI: 0.16-0.67 for colonic location
      Smoking P = 0.17 NS
      Perianal disease P = 0.19 NS
      Anaemia at presentation P < 0.001, OR = 2.79 P < 0.001, OR = 4.39
95%CI: 1.73-4.51 95%CI: 2.37-8.11
1According to Montreal classification; 2If all locations were considered. NS: Non-significant.
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CD­related inpatient stay decreased from 17 to 11 
days between 1991 and 2001. Fifty-two percent of CD 
patients were admitted and 40% readmitted within 
five years of diagnosis. Twenty-seven percent had a 
CD-related surgery with 15% readmitted for surgery. 
During the 15 years’ follow­up, 80% of admissions and 
64% of surgeries were within five years of diagnosis. 
Concordantly, in the present study, the mean inpatient 
stay was 9.87 d in the year of the diagnosis, with rates 
in the subsequent three years decreasing significantly 
by 1.2-1.7 d annually. Of note, 46.7% of all CD-related 
hospitalizations occurred within one year of diagnosis, 
while 27.8%, 11.8%, and 13.7% of these events 
occurred between two to four, five to six, and seven 
to ten years after diagnosis. Comparable data were 
reported recently from Denmark, where hospitalization 
duration decreased from seven days per patient within 
one year of diagnosis to 0.9 d at year five[15].
The indication for hospitalization may be dependent 
on additional factors other than disease severity, 
including health insurance reimbursement policies 
and ethnic differences. For example, data from Kaiser 
Permanente Northern California (a health maintenance 
organization) suggested that hospitalization rates for 
Crohn’s disease decreased by 33% between 1998 and 
2005[22]. The reasons for this rapid change are not 
clear.
As discussed above, major surgery represents 
30%-50% of all CD-related hospitalization events. 
While data suggest a decrease in recent surgical 
rates[3] the majority of the studies report stable or 
only slightly fluctuating hospitalization rates after the 
1970’s. Early studies reported higher surgery rates. 
In Stockholm, surgical rates were 30%, 50%, and 
60% after 5, 10, and 15 years between 1955­1974 in a 
population­based study, while surgery rates were stable 
until 1989[23]. Similar to the present study and the data 
from Manitoba, in a more recent pre-biologic population-
based cohort from Norway, (IBSEN) cumulative surgery 
rates in the 1990s were 14%, 27%, and 38% after one, 
five and ten years of diagnosis, respectively[24].
The indications for hospitalization may include 
diagnostic procedures, active disease requiring medical 
or surgical treatment, treatment related complications 
(side effects, infections), or unrelated causes. In a 
population­based study from Olmstead county[5] factors 
associated with first hospitalization included location 
(ileocolonic, small bowel, or upper gastrointestinal 
disease), and non-inflammatory behavior at baseline. 
In a further study from Canada, CD patients requiring 
hospitalization were more likely than UC cases to be 
female and younger[6]. Similarly, in the present study 
non-inflammatory disease behavior at diagnosis (HR 
= 1.32, P = 0.001), perianal disease (HR = 1.47, P = 
0.04) were associated with time to first hospitalization 
while disease behavior change (HR = 2.38, P = 0.002) 
and need for steroids (HR = 3.14, P = 0.003) were 
associated with time to first re-hospitalization in multiple 
Cox-regression analyses. More data are available 
on predictors of surgery, including disease location, 
complicated disease behavior, perianal disease, 
smoking, medical strategy, and age at onset[3,25]. In 
addition, the association between arthritis and need 
for immunosuppressives reported in the present study 
warrants further investigations. However, a possible 
explanation is that extraintestinal manifestations may 
be regarded as markers of patients with systemic 
disease leading to more aggressive therapeutic 
strategy. Finally, the need for early hospitalization was 
identified as an independent marker of later disease 
course, and was associated with immunosuppressive 
use and surgery; this represents a major finding of 
this study.
The authors are aware of the possible limitations of 
the study. The indication for hospitalization is somewhat 
subjective and may be influenced by factors other than 
disease severity, such as insurance reimbursement or 
center protocols. In this study group, reimbursement 
policy and patient management did not change 
significantly in the during the study period. The main 
specialists delivering the majority of IBD care also 
remained the same. A further strength of the study is 
its population­based design, which enabled study of the 
full disease spectrum, including both mild and severe 
forms. We believe that this allows a more objective 
assessment of importance of possible predictors, 
which may not be possible in a solely referral­patient 
population. Thus data obtained in population-based 
setting are more objective in assess disease outcomes 
and enable generalizability of the findings to real-life 
IBD populations. Finally, an advantage of the present 
study was that we aimed to study the era after the 
approval introduction of biologicals. Thus, for the first 
time, we could investigate and report the change of 
hospitalization rates and indications of hospitalizations 
in the era of increasing biological use. Interestingly, 
only a relatively small proportion of CD patients were 
exposed to anti-TNFs. Nonetheless, our study provides 
an up­to­date view on the patterns and reasons for 
hospitalization in patients with Crohn’s disease. In 
addition, our data can contribute to the more accurate 
planning of health care access requirements of CD 
patients during the first 5-10 years of their disease.
In conclusion, hospitalization and re­hospitalization 
rates were still relatively high in this population­based 
cohort; almost half of disease­related hospitalizations 
occurred within one year of diagnosis. Subsequently, 
the average duration of hospitalization decreased 
significantly. Non-inflammatory disease behavior 
at diagnosis was identified as the pivotal predictive 
factor of hospitalization and re-hospitalization. Early 
hospitalization requirements were independently 
associated with clinical outcomes (need for immuno­
suppressives and surgery).
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Background
Hospitalizations are important outcome measures and major cost drivers in 
inflammatory bowel diseases. Recent clinical trials suggest that aggressive 
medical therapy leads to decreased hospitalization requirements. Recent data 
on hospitalization rates in Crohn’s disease (CD) from real life settings are 
lacking from population-based studies.
Research frontiers
Limited data are available from population-based studies regarding health 
care utilization, including hospitalization requirements in CD from the era of 
biologicals.
Innovations and breakthroughs
Hospitalization and re-hospitalization rates are still high in this cohort. 
Non-inflammatory disease behavior at diagnosis was identified as the 
pivotal predictive factor of both hospitalization and re-hospitalization. Early 
hospitalization requirement was independently associated with clinically 
significant outcomes.
Applications
New data from this population-based cohort will help in predicting health care 
utilization requirements in CD patients in the current era which is important for 
both health care professionals and insurance companies. In addition, time-
trends and predictors of hospitalizations were determined.
Terminology
The main goal of the present study was to determine the inflammatory bowel 
diseases-related and all-cause first- and re-hospitalization rates during the first 
5-years after the diagnosis stratified by disease duration and investigate the 
role of possible predictors.
Peer-review
The paper analyzes the factors influencing hospitalization rates in a subset of 
patients affected by CD. The paper is well written, inclusion/exclusion criteria 
and study protocol are appropriate; statistical analysis is proper and accurate.
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